The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer – New Combinational Approaches and Strategies of Neovessel Inhibition
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-01-05
DOI
10.3389/fcell.2020.610903
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cholesterol-lowering drug pitavastatin targets lung cancer and angiogenesis via suppressing prenylation-dependent Ras/Raf/MEK and PI3K/Akt/mTOR signaling
- (2020) Tianjun Hu et al. ANTI-CANCER DRUGS
- An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates
- (2020) Jermaine Goveia et al. CANCER CELL
- Single-Cell RNA Sequencing Maps Endothelial Metabolic Plasticity in Pathological Angiogenesis
- (2020) Katerina Rohlenova et al. Cell Metabolism
- The clinical significance of CXCL16 in the treatment of advanced non‐small cell lung cancer
- (2020) Yuji Shibata et al. Thoracic Cancer
- Real-world treatment efficacy of anti-programmed death-1 combined with anti-angiogenesis therapy in non-small cell lung cancer patients
- (2020) Lupeng Qiu et al. MEDICINE
- Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
- (2020) Catherine Overed-Sayer et al. THORAX
- Therapeutic paradigm of dual targeting VEGF and PDGF for effectively treating FGF-2 off-target tumors
- (2020) Kayoko Hosaka et al. Nature Communications
- The Design, Characterizations, and Tumor Angiogenesis Inhibition of a Multi-Epitope Peptibody With bFGF/VEGFA
- (2020) Ligang Zhang et al. Frontiers in Oncology
- Therapeutic angiogenesis: From conventional approaches to recent nanotechnology-based interventions
- (2019) Robin Augustine et al. Materials Science & Engineering C-Materials for Biological Applications
- Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells
- (2019) Jun Lu et al. BMC Medical Genomics
- Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
- (2019) Haruhiro Saito et al. LANCET ONCOLOGY
- Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
- (2019) Yushu Joy Xie et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Apelin inhibition prevents resistance and metastasis associated with anti‐angiogenic therapy
- (2019) Iris Uribesalgo et al. EMBO Molecular Medicine
- miR‑195 suppresses metastasis and angiogenesis of squamous cell lung cancer by inhibiting the expression of VEGF
- (2019) Hailin Liu et al. Molecular Medicine Reports
- MicroRNA-130b functions as an oncomiRNA in non-small cell lung cancer by targeting tissue inhibitor of metalloproteinase-2
- (2019) Takayuki Hirono et al. Scientific Reports
- Hallmarks of Endothelial Cell Metabolism in Health and Disease
- (2019) Xuri Li et al. Cell Metabolism
- Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
- (2019) Roy S Herbst et al. LANCET ONCOLOGY
- Targeting Tumor Endothelial Cells with Nanoparticles
- (2019) Sakurai et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- TEM8/ANTXR1-specific CAR T cells mediate toxicity in vivo
- (2019) Kristina Petrovic et al. PLoS One
- Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment
- (2019) Dorcas A. Annan et al. Cell Communication and Signaling
- Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Kazuhiko Nakagawa et al. LANCET ONCOLOGY
- Tumor Angiogenesis and Anti-Angiogenic Strategies for Cancer Treatment
- (2019) Raluca Ioana Teleanu et al. Journal of Clinical Medicine
- Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
- (2018) Baohui Han et al. BRITISH JOURNAL OF CANCER
- Antiangiogenic therapies in non-small-cell lung cancer
- (2018) A. Alshangiti et al. Current Oncology
- The regulatory role of microRNAs in angiogenesis-related diseases
- (2018) Li-Li Sun et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Endothelial Tie1–mediated angiogenesis and vascular abnormalization promote tumor progression and metastasis
- (2018) Silvia La Porta et al. JOURNAL OF CLINICAL INVESTIGATION
- Phenotype molding of stromal cells in the lung tumor microenvironment
- (2018) Diether Lambrechts et al. NATURE MEDICINE
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- The dark side of tumor-associated endothelial cells
- (2018) Francesco De Sanctis et al. SEMINARS IN IMMUNOLOGY
- Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease
- (2018) Dhruv R. Seshadri et al. Frontiers in Pharmacology
- Anti-Angiogenics: Their Value in Lung Cancer Therapy
- (2018) Melanie Janning et al. Oncology Research and Treatment
- TTF-1 Expression Predicts the Merit of Additional Antiangiogenic Treatment in Non-squamous Non-small Cell Lung Cancer
- (2018) AKIRA TAKEUCHI et al. ANTICANCER RESEARCH
- Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation
- (2018) Ulrike Bruning et al. Cell Metabolism
- Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive non-squamous non–small-cell lung cancer (NSCLC): Survival follow-up results of JO25567.
- (2018) Noboru Yamamoto et al. JOURNAL OF CLINICAL ONCOLOGY
- PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
- (2018) Tianrun Liu et al. Nature Communications
- Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Cesare Gridelli et al. JAMA Oncology
- Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Baohui Han et al. JAMA Oncology
- Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for non-small cell lung cancer therapy
- (2018) Jun Lu et al. EUROPEAN RESPIRATORY JOURNAL
- The role of sema4D in vasculogenic mimicry formation in non-small cell lung cancer and the underlying mechanisms
- (2018) Yun Xia et al. INTERNATIONAL JOURNAL OF CANCER
- Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer
- (2017) Martin Reck et al. LUNG CANCER
- Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin
- (2017) Daniel Delgado-Bellido et al. Molecular Cancer
- Hypoxic lung cancer-secreted exosomal miR-23a increased angiogenesis and vascular permeability by targeting prolyl hydroxylase and tight junction protein ZO-1
- (2017) Y-L Hsu et al. ONCOGENE
- Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer
- (2017) Nusrat Chowdhury et al. PHARMACEUTICAL RESEARCH
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Mast cells decrease efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme B
- (2017) M. Wroblewski et al. Nature Communications
- Inhibition of the Glycolytic Activator PFKFB3 in Endothelium Induces Tumor Vessel Normalization, Impairs Metastasis, and Improves Chemotherapy
- (2016) Anna Rita Cantelmo et al. CANCER CELL
- Dual blockade of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) exhibits potent anti-angiogenic effects
- (2016) Dong Li et al. CANCER LETTERS
- Cell behaviors and dynamics during angiogenesis
- (2016) Charles Betz et al. DEVELOPMENT
- Tumor angiogenesis—characteristics of tumor endothelial cells
- (2016) Kyoko Hida et al. International Journal of Clinical Oncology
- Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation
- (2016) Minah Kim et al. JOURNAL OF CLINICAL INVESTIGATION
- Tie1 controls angiopoietin function in vascular remodeling and inflammation
- (2016) Emilia A. Korhonen et al. JOURNAL OF CLINICAL INVESTIGATION
- Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models
- (2016) Victoria L Bridgeman et al. JOURNAL OF PATHOLOGY
- Antiangiogenic therapy in oncology: current status and future directions
- (2016) Gordon C Jayson et al. LANCET
- Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer
- (2016) Analia Rodríguez Garzotto et al. MEDICAL ONCOLOGY
- Angiocrine functions of organ-specific endothelial cells
- (2016) Shahin Rafii et al. NATURE
- Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
- (2016) Yufang Shi et al. NATURE REVIEWS DRUG DISCOVERY
- Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
- (2016) Teresa E. Peterson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vasculogenic mimicry in small cell lung cancer
- (2016) Stuart C. Williamson et al. Nature Communications
- Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
- (2016) Yunlong Yang et al. Nature Communications
- Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?
- (2016) Ana Luísa Coelho et al. Oncotarget
- When tumors are (co-)opting to resist anti-angiogenic treatment
- (2016) Lasse D. Jensen Translational Cancer Research
- VEGF-A Expression Correlates with TP53 Mutations in Non-Small Cell Lung Cancer: Implications for Antiangiogenesis Therapy
- (2015) M. Schwaederle et al. CANCER RESEARCH
- Analysis of patient-reported outcomes from the LUME-Lung 1 trial: A randomised, double-blind, placebo-controlled, Phase III study of second-line nintedanib in patients with advanced non-small cell lung cancer
- (2015) Silvia Novello et al. EUROPEAN JOURNAL OF CANCER
- Tryptase, a novel angiogenic factor stored in mast cell granules
- (2015) Domenico Ribatti et al. EXPERIMENTAL CELL RESEARCH
- Erlotinib-Cisplatin Combination Inhibits Growth and Angiogenesis through c-MYC and HIF-1α in EGFR-Mutated Lung Cancer In Vitro and In Vivo
- (2015) Jasmine G. Lee et al. NEOPLASIA
- Understanding high endothelial venules: Lessons for cancer immunology
- (2015) Ann Ager et al. OncoImmunology
- A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin-Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: Results of the Phase II Randomized ABIGAIL Study (BO21015)
- (2014) Tony Mok et al. Journal of Thoracic Oncology
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial
- (2014) Martin Reck et al. LANCET ONCOLOGY
- Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
- (2014) Takashi Seto et al. LANCET ONCOLOGY
- Functional polarization of tumour-associated macrophages by tumour-derived lactic acid
- (2014) Oscar R. Colegio et al. NATURE
- Glioblastoma: A Pathogenic Crosstalk between Tumor Cells and Pericytes
- (2014) Elisabetta M. Caspani et al. PLoS One
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- Role of PFKFB3-Driven Glycolysis in Vessel Sprouting
- (2013) Katrien De Bock et al. CELL
- Strategies for advancing cancer nanomedicine
- (2013) Vikash P. Chauhan et al. NATURE MATERIALS
- Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?
- (2013) Tom Donnem et al. Cancer Medicine
- Regulation of tumor-associated high-endothelial venules by dendritic cells
- (2013) Ludovic Martinet et al. OncoImmunology
- Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer
- (2012) J.-C. Soria et al. ANNALS OF ONCOLOGY
- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Bradykinin Promotes the Chemotactic Invasion of Primary Brain Tumors
- (2011) V. Montana et al. JOURNAL OF NEUROSCIENCE
- Molecular mechanisms and clinical applications of angiogenesis
- (2011) Peter Carmeliet et al. NATURE
- Angiogenesis
- (2011) D. R. Senger et al. Cold Spring Harbor Perspectives in Biology
- Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- (2010) M. Reck et al. ANNALS OF ONCOLOGY
- Mast cells, angiogenesis, and tumour growth
- (2010) Domenico Ribatti et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Signalling pathways in vasculogenic mimicry
- (2010) Yvette W.J. Paulis et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature
- (2010) De-Hong Yu et al. BIOMATERIALS
- Matrix Metalloproteinases: Regulators of the Tumor Microenvironment
- (2010) Kai Kessenbrock et al. CELL
- Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
- (2010) Lucio Crinò et al. LANCET ONCOLOGY
- Inositol-requiring enzyme 1 is a key regulator of angiogenesis and invasion in malignant glioma
- (2010) G. Auf et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy
- (2009) S. J. Priceman et al. BLOOD
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- PDGF-C Mediates the Angiogenic and Tumorigenic Properties of Fibroblasts Associated with Tumors Refractory to Anti-VEGF Treatment
- (2009) Yongping Crawford et al. CANCER CELL
- Cytokines in bronchoalveolar lavage fluid and serum of lung cancer patients during radiotherapy — Association of interleukin-8 and VEGF with survival
- (2009) Marika Crohns et al. CYTOKINE
- Angiogenesis in pre-malignant conditions
- (2009) Marius Raica et al. EUROPEAN JOURNAL OF CANCER
- Mast cell phenotypes and microvessels in non–small cell lung cancer and its prognostic significance
- (2009) María José Carlini et al. HUMAN PATHOLOGY
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL
- (2009) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Control of vascular morphogenesis and homeostasis through the angiopoietin–Tie system
- (2009) Hellmut G. Augustin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now